{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:24:45Z","timestamp":1793107485252,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of patients with differentiated thyroid cancers (DTCs) at low risk for disease progression or relapse after treatment remains controversial. These patients have excellent disease-specific survival. Therefore, minimizing the impact of treatments on patients\u2019 quality of life is particularly important. For these reasons, the pendulum has swung in recent years to favor less extensive surgery toward lobectomy instead of total thyroidectomy, away from prophylactic (central compartment) lymphadenectomy, and even in some cases, omitting surgery altogether. This review discusses several of the influential studies from the past two decades that have had an impact on the management for these patients, including a shift toward more personalized care.<\/jats:p>","DOI":"10.1245\/s10434-025-17063-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T10:04:38Z","timestamp":1740564278000},"page":"3119-3125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Landmark Series: Extent of Surgery for Low-Risk Differentiated Thyroid Cancer"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-789X","authenticated-orcid":false,"given":"Timothy M.","family":"Ullmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"17063_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"17063_CR2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/SLA.0000000000000925","volume":"260","author":"MA Adam","year":"2014","unstructured":"Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601\u20137.","journal-title":"Ann Surg"},{"key":"17063_CR3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cncr.30360","volume":"123","author":"BR Haugen","year":"2017","unstructured":"Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123:372\u201381.","journal-title":"Cancer"},{"key":"17063_CR4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022;386:923\u201332.","journal-title":"N Engl J Med"},{"key":"17063_CR5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/SLA.0000000000004345","volume":"272","author":"RS Sippel","year":"2020","unstructured":"Sippel RS, Robbins SE, Poehls JL, et al. A randomized controlled clinical trial: no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer. Ann Surg. 2020;272:496\u2013503.","journal-title":"Ann Surg"},{"key":"17063_CR6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.surg.2021.03.071","volume":"171","author":"J-H Ahn","year":"2022","unstructured":"Ahn J-H, Kwak JH, Yoon SG, et al. A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma. Surgery. 2022;171:182\u20139.","journal-title":"Surgery"},{"key":"17063_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2021.0539","volume":"32","author":"R Chou","year":"2022","unstructured":"Chou R, Dana T, Haymart M, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid. 2022;32:351\u201367.","journal-title":"Thyroid"},{"key":"17063_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/clinem\/dgab917","volume":"107","author":"MN Stan","year":"2022","unstructured":"Stan MN, Papaleontiou M, Schmitz JJ, et al. Nonsurgical management of thyroid nodules: the role of ablative therapies. J Clin Endocrinol Metab. 2022;107:1417\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"17063_CR9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/SLA.0000000000002864","volume":"269","author":"BT Fry","year":"2019","unstructured":"Fry BT, Campbell DA, Englesbe MJ, et al. Using patient-reported outcomes to enhance appropriateness in low-risk elective general surgery. Ann Surg. 2019;269:41\u20132.","journal-title":"Ann Surg"},{"key":"17063_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/clinem\/dgac646","volume":"108","author":"TM Ullmann","year":"2023","unstructured":"Ullmann TM, Papaleontiou M, Sosa JA. Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis. J Clin Endocrinol Metab. 2023;108:271\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"17063_CR11","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/clinem\/dgad282","volume":"108","author":"AS Alzahrani","year":"2023","unstructured":"Alzahrani AS. Clinical use of molecular data in thyroid nodules and cancer. J Clin Endocrinol Metab. 2023;108:2759\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"17063_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/SLA.0b013e31814697d9","volume":"246","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375\u201381.","journal-title":"Ann Surg"},{"key":"17063_CR13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167\u2013214.","journal-title":"Thyroid"},{"key":"17063_CR14","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1245\/s10434-014-3516-x","volume":"21","author":"H In","year":"2014","unstructured":"In H, Bilimoria KY, Stewart AK, et al. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21:1520\u20139.","journal-title":"Ann Surg Oncol"},{"key":"17063_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamasurg.2021.6442","volume":"157","author":"W Chen","year":"2022","unstructured":"Chen W, Li J, Peng S, et al. Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence. JAMA Surg. 2022;157:200\u20139.","journal-title":"JAMA Surg"},{"key":"17063_CR16","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1245\/s10434-014-3846-8","volume":"21","author":"A Hauch","year":"2014","unstructured":"Hauch A, Al-Qurayshi Z, Randolph G, et al. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844\u201352.","journal-title":"Ann Surg Oncol"},{"key":"17063_CR17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.eprac.2021.01.005","volume":"27","author":"CC Lubitz","year":"2021","unstructured":"Lubitz CC, Kiernan CM, Toumi A, et al. Patient perspectives on the extent of surgery and radioactive iodine treatment for low-risk differentiated thyroid cancer. Endocr Pract. 2021;27:383\u20139.","journal-title":"Endocr Pract"},{"key":"17063_CR18","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/thy.2019.0590","volume":"30","author":"S Ahmadi","year":"2020","unstructured":"Ahmadi S, Gonzalez JM, Talbott M, et al. Patient preferences around extent of surgery in low-risk thyroid cancer: a discrete choice experiment. Thyroid. 2020;30:1044\u201352.","journal-title":"Thyroid"},{"key":"17063_CR19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126:1052\u201366.","journal-title":"J Clin Invest"},{"key":"17063_CR20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/thy.2016.0350","volume":"27","author":"S Moon","year":"2017","unstructured":"Moon S, Song YS, Kim YA, et al. Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid. 2017;27:651\u201360.","journal-title":"Thyroid"},{"key":"17063_CR21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","volume":"3","author":"R Liu","year":"2017","unstructured":"Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E, and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 2017;3:202\u20138.","journal-title":"JAMA Oncol"},{"key":"17063_CR22","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-21-0874","volume":"27","author":"T Pappa","year":"2021","unstructured":"Pappa T, Ahmadi S, Marqusee E, et al. Oncogenic mutations in PI3K\/AKT\/mTOR pathway effectors associate with worse prognosis in BRAFV600E -driven papillary thyroid cancer patients. Clin Cancer Res. 2021;27:4256\u201364.","journal-title":"Clin Cancer Res"},{"key":"17063_CR23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoto.2023.1494","volume":"149","author":"MA Schumm","year":"2023","unstructured":"Schumm MA, Shu ML, Hughes EG, et al. Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or known (Bethesda VI) papillary thyroid cancer. JAMA Otolaryngol Head Neck Surg. 2023;149:735\u201342.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"17063_CR24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/thy.2021.0557","volume":"32","author":"E Pasqual","year":"2022","unstructured":"Pasqual E, Sosa JA, Chen Y, et al. Trends in the management of localized papillary thyroid carcinoma in the United States (2000\u20132018). Thyroid. 2022;32:397\u2013410.","journal-title":"Thyroid"},{"key":"17063_CR25","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2011-2512","volume":"97","author":"C Schvartz","year":"2012","unstructured":"Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526\u201335.","journal-title":"J Clin Endocrinol Metab"},{"key":"17063_CR26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1210\/jc.2014-3882","volume":"100","author":"L Lamartina","year":"2015","unstructured":"Lamartina L, Durante C, Filetti S, et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"17063_CR27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/thy.2011.0317","volume":"22","author":"T Carling","year":"2012","unstructured":"Carling T, Carty SE, Ciarleglio MM, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22:237\u201344.","journal-title":"Thyroid"},{"key":"17063_CR28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/105072503321669875","volume":"13","author":"Y Ito","year":"2003","unstructured":"Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381\u20137.","journal-title":"Thyroid"},{"key":"17063_CR29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00268-009-0303-0","volume":"34","author":"Y Ito","year":"2010","unstructured":"Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28\u201335.","journal-title":"World J Surg"},{"key":"17063_CR30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.surg.2021.07.043","volume":"171","author":"JH Kuo","year":"2022","unstructured":"Kuo JH, Sinclair CF, Lang B, et al. A comprehensive review of interventional ablation techniques for the management of thyroid nodules and metastatic lymph nodes. Surgery. 2022;171:920\u201331.","journal-title":"Surgery"},{"key":"17063_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamasurg.2023.5202","volume":"159","author":"X Li","year":"2024","unstructured":"Li X, Yan L, Xiao J, et al. Long-term outcomes and risk factors of radiofrequency ablation for T1N0M0 papillary thyroid carcinoma. JAMA Surg. 2024;159:51\u20138.","journal-title":"JAMA Surg"},{"key":"17063_CR32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12020-023-03502-8","volume":"83","author":"T Ledesma-Leon","year":"2024","unstructured":"Ledesma-Leon T, Solis-Pazmino P, Lincango EP, et al. Ablation techniques or active surveillance compared to surgical resection in patients with low-risk papillary thyroid cancer: a systematic review and meta-analysis. Endocrine. 2024;83:330\u201341.","journal-title":"Endocrine"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:32:47Z","timestamp":1744079567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["17063"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17063-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Julie A. Sosa is a member of the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry supported by Novo Nordisk, Astra Zeneca and Eli Lilly. She received institutional research funding from Exelixis and Eli Lilly. Timothy M. Ullmann has no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}